SS Innovations International, Inc. (NASDAQ: SSII) has announced significant growth in the adoption and utilization of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of September 8, 2026—a 79% increase from 7,885 at the end of 2025. The installed base of SSi Mantra systems rose 42% to 238 units from 168 during the same period. These figures underscore the company's expanding footprint in the global surgical robotics market and suggest growing acceptance of its cost-effective alternative to established robotic surgery platforms.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the system, which has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the company's strategy to make robotic surgery accessible in both developed and emerging markets, potentially reshaping how surgical care is delivered in regions where advanced robotic systems have historically been scarce.
SS Innovations also reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of August 31, including a more than 13,600-mile telesurgery between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, demonstrating the system's capacity for high-volume use. Such milestones are critical as they validate the reliability and scalability of the SSi Mantra platform, which could drive further adoption among hospitals seeking to improve surgical outcomes while managing costs.
Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027 and believes European Union CE marking certification can be obtained by year-end 2026. Regulatory approvals in these key markets would significantly expand SS Innovations' addressable market and provide a pathway for increased revenue growth. The company's progress toward these certifications is a key indicator of its potential to compete with larger, more established players in the surgical robotics industry.
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. Its product range includes the proprietary SSi Mantra surgical robotic system and the comprehensive suite of SSi Mudra surgical instruments, which support a variety of procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
For investors, the company's latest news and updates are available in its newsroom at https://ibn.fm/SSII. A full report on the recent milestones can be viewed at https://ibn.fm/DJILj. The rapid adoption of the SSi Mantra system, coupled with upcoming regulatory decisions, positions SS Innovations as a notable contender in the global surgical robotics market, with implications for both patient access to advanced surgical care and the company's growth trajectory.
